Razaxaban
Alternative Names: BMS 561389; DPC 906Latest Information Update: 26 Sep 2006
At a glance
- Originator Bristol-Myers Squibb
- Class Anticoagulants; Antithrombotics; Isoxazoles; Pyrazoles; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Dec 2004 Discontinued - Phase-II for Thrombosis in USA (PO)
- 16 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the adverse events and Thrombosis pharmacodynamics and therapeutic trials sections ,
- 22 May 2001 Phase-II clinical trials for Thrombosis in USA (PO)